March 27, 2018 — The U.S. Food and Drug Administration (FDA) has cleared Siemens Healthineers’ Mammomat Revelation premium mammography platform with the new InSpect integrated specimen imaging tool and the new HD Breast Biopsy solution for one-click targeting of suspicious areas. These and other features are designed to expand precision medicine and improve the patient experience.
Mammomat Revelation’s InSpect integrated specimen imaging tool permits imaging and real-time review of biopsy samples at the workstation. This tool improves biopsy workflow, shortens compression time and reduces patient discomfort.
HD Breast Tomosynthesis offers the widest image acquisition angle available at 50 degrees, according to Siemens. The wide angle delivers what the company calls the industry’s highest depth resolution for better separation of overlapping breast tissue, providing high-quality 3-D images for improved diagnostic confidence and earlier lesion detection. This technology is the basis for Mammomat Revelation’s HD Breast Biopsy solution, which enables one-click targeting of suspicious areas with a +/- 1mm accuracy.
Nearly half of all women in the United States who receive mammograms have dense breasts,¹ complicating efforts to identify breast lesions. Typically, the radiologist assesses fibroglandular breast density visually after the patient has left the facility. Mammomat Revelation is the first platform to offer automated breast density measurement during the mammogram for immediate, personalized risk stratification and more personalized care.
Mammomat Revelation’s Personalized Soft Compression adjusts the level of breast compression automatically to suit each patient’s anatomy. Coupled with ergonomic SoftComp Paddles, Personalized Soft Compression enables improved breast positioning, more consistent image quality, and less discomfort and anxiety.
And for inconclusive cases, the system offers titanium contrast-enhanced mammography as a cost-effective alternative to magnetic resonance imaging (MRI), reducing scheduling conflicts and reassuring the patient.
For more information: www.usa.healthcare.siemens.com
References
1. National Cancer Institute, https://www.cancer.gov/types/breast/breast-changes/dense-breasts
March 06, 2026 
